Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Vanguard Real Estate Index Fund ETF — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Vanguard Real Estate Index Fund ETF trades at $90.38 (market cap $70.80B). The key difference: Vanguard Real Estate Index Fund ETF is far larger — about 14.5× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Vanguard Real Estate Index Fund ETF for 113 Days on average.
| TVTX | VNQ | |
|---|---|---|
Market Cap | $4.88B | $70.80B |
Volume | 1,668,577 | 3,568,223 |
Sector | Health | — |
52-Week High | $67.52 | $100.95 |
52-Week Low | $26.79 | $87.00 |
Typical Hold Time | 0 Days | 113 Days |
Enterprise Value | $5.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
VNQ, the Vanguard Real Estate ETF, trades at $91.14, down 0.24% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. Recent news highlights pressure from rising Treasury yields and Fed rate hikes, contributing to a nearly 10% decline over the past month. The ETF's dividend yield is now competitive with T-bills, but sector headwinds persist due to interest rate sensitivity.
Outlook remains cautious amid interest rate uncertainty, with potential long-term value for contrarian investors. Risks include further rate hikes eroding income appeal, while opportunities lie in historically attractive entry points for well-capitalized REITs. Investors should weigh yield sustainability against macroeconomic trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
